ONWARD, Eindhoven (2026)

08/01/2026

“Most people don't realize how important blood pressure is until they lose control of it,” says Nuno Abreu.

In 2021, Nuno, a general surgeon based in Lisbon, Portugal, sustained a spinal cord injury in a bodyboarding accident. In addition to adjusting to life in a wheelchair, he faced another, invisible and debilitating challenge: blood pressure instability.

After spinal cord injury, many people experience symptomatic blood pressure instability, where disruptions in the autonomic nervous system cause blood pressure to fluctuate between abnormally low and high levels. Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and overall quality of life.

▶️ Nuno is a clinical trial participant. Hear directly from him about how our investigational ARC-IM® System, an implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation, has helped him manage his blood pressure and feel better day to day.

The ARC-IM System is currently being evaluated as part of Empower BP, a global pivotal study assessing the safety and efficacy of the implantable neurostimulation technology in addressing blood pressure instability following .

For more details about the study, please visit the link in the comments below.

ARC-IM® is investigational and not available for commercial use.

05/01/2026

We are thrilled to announce the recent delivery of the first ARC-EX® Systems in Europe.

NeuroMove, located in Amsterdam, The Netherlands, is one of the first clinics to receive our groundbreaking spinal cord stimulation therapy, indicated to improve hand strength and sensation after spinal cord injury.

Thank you, Team NeuroMove, for your engagement during our training sessions, and for the essential work you’re doing every day to deliver care to those living with spinal cord injuries.

We look forward to continuing the launch of the ARC-EX System and to offering new recovery and care options for the community across Europe.

ARC-EX Indication for Use (EU): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic and with take-home exercises in the home to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic (>1 year post-injury), non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).

Photos by Marcel Valkema

19/12/2025

We're delighted to have partnered with Jessie Owen for this year's festive season card.

Jessie lives with a cervical spinal cord injury sustained over a decade ago, which left her paralyzed. A trailblazer and clinical trial participant, she embraced our pioneering spinal cord stimulation technology, which is now accessible to the broader community in the US and Europe. It helped her regain movement, function, and independence after her accident. Crucially, it enabled her to return to activities that bring her joy – such as painting.

This festive season, we are proud to share Jessie’s art with you. We hope you feel as much joy when you look at it as we do. We celebrate a journey of resilience, hope, and creativity. Empowered by independence.

11/12/2025

We are proud to announce that VITREA will be the first large rehabilitation network to offer the groundbreaking ARC-EX® Therapy in Europe, starting with two clinics in Switzerland VITREA Schweiz.

and are being equipped with ONWARD's external spinal cord stimulation systems, indicated to improve hand strength and sensation after spinal cord injury .

Thank you, Conny Cox, Klaus Schuster, Dr. med. Daniel Zutter, and the VITREA Teams for your commitment to opening new doors for the community in Europe by bringing innovative therapy options to the people you care for every day.

The ARC-EX System was selected as a TIME Magazine Best Invention and recognized as one of Fast Company's 2025 World Changing Ideas for its potential to transform lives. We have started its phased launch in Europe, and are committed to making it broadly accessible to the European SCI community in 2026.

ARC-EX Indication for Use (EU): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic and with take-home exercises in the home to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic (>1 year post-injury), non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).

17/11/2025

We are pleased to announce that we have received clearance to expand the ARC-EX System indication for home use in the US. The Food and Drug Administration has cleared the ARC-EX System for use in conjunction with functional task practice in the clinic and take-home exercises in the home to improve hand strength and sensation in adults with spinal cord injury.

“For people with limited mobility who navigate daily logistical challenges, having the option to use this therapy at home can make a meaningful difference. Integrating in-clinic and at-home therapy may help support and maintain improvements in hand strength and sensation, contributing positively to overall quality of life,” said Dr. Candy Tefertiller, PT, DPT, PhD, NCS, Executive Director of Research and Evaluation at Craig Hospital in Denver, Colorado.

“For more than 40 years, the Christopher & Dana Reeve Foundation and our community have invested boldly in high-risk, high-reward science, pairing funding and leadership with the lived experience of those living with and those who care for them. Today’s achievement demonstrates that we are now seeing breakthroughs once thought impossible,” said Marco Baptista, Ph.D., Chief Scientific Officer of the Christopher & Dana Reeve Foundation.

The ARC-EX System is non-invasive and delivers programmed, transcutaneous electrical spinal cord stimulation. It is intended to be operated in medical centers by rehabilitation professionals and at home by patients and persons providing assistance to patients, as needed.

ARC-EX Indication for Use (US): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic and with take-home exercises in the home to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, nonprogressive neurological deficits resulting from an incomplete spinal cord injury (C2-C8 inclusive). The ARC-EX System is intended to be operated in medical centers by rehabilitation professionals and at home by patients and persons providing assistance to patients, as needed.

11/11/2025

"I always wanted to join the military. I've traveled the world and done all sorts of things. You've got to always be optimistic and find the good in whatever situation you're in. I may not be able to walk again, but there are always new things to learn to make my life easier. Since using the technology, I've noticed many minor things that, to me, are major. I like playing spades. Now I can hold the cards up with one hand or with both hands and pull them out without worrying about dropping them. Little things like that make a big difference."

AJ Walker is a US Navy veteran living with spinal cord injury, and a user of our technology designed to improve hand sensation and strength after . This Veterans Day, we honor all who have served and recognize their courage and resilience. Our team is dedicated to helping people living with SCI enjoy life in the ways that matter to them. Thank you, AJ, for your service and for sharing your motivating outlook and drive!

Patient testimonials reflect individual experiences and outcomes, which may vary. Please review the full product label and clinical study data.

28/10/2025

We’re happy to announce that long-time ONWARD Medical partner Scott Chesney has received the Mike Lione Accessibility Award!

This award is given to pioneers and visionaries in accessibility who have performed exemplary work as advocates for people living with disabilities. Scott is a long-time champion and advocate for the spinal cord injury community, and has offered us an invaluable perspective as we work together to raise awareness on the importance of accessibility and empowering movement.

Congratulations, Scott, on this well-earned recognition! 🏆

17/10/2025

"Without blood pressure, blood doesn’t flow through your body. It’s like a garden hose that’s not watering the plants. Your organs don’t get the oxygen and blood they need. Blood pressure is central to everything."

That is how Nuno Abreu, a general surgeon in Lisbon, Portugal, living with spinal cord injury (SCI), describes the need for improved blood pressure regulation.

After , many people experience symptomatic blood pressure instability, where disruptions in the autonomic nervous system cause blood pressure to fluctuate between abnormally low and high levels. Blood pressure instability and persistent low blood pressure can threaten neurological recovery and negatively impact cardiovascular health and overall quality of life.

“I had severe hypotension after my SCI. I wasn’t able to be upright for a long time, and I fainted multiple times a day,” explains Julie Verlinden.

In collaboration with the Christopher & Dana Reeve Foundation, we recently hosted a webinar ahead of the initiation of Empower BP, a global pivotal study to assess the safety and effectiveness of our implantable neurostimulation technology in addressing blood pressure instability following SCI.

📺 Watch the full webinar to learn more about Nuno's and Julie’s experiences, and about the Empower BP global pivotal study: https://www.youtube.com/watch?v=5mW8TlLnnak

For more details about the study, please visit: https://www.onwd.com/empower-bp/

ARC-IM® is investigational and not available for commercial use. Limited by United States law to investigational use. To stay informed about ONWARD’s technologies, research studies, and future availability in your area, please complete the web form linked in the comments below.

24/09/2025

Reminder: Webinar is Tomorrow!

Join us tomorrow, September 25 at 12:00 PM ET, co-hosted with the Christopher & Dana Reeve Foundation, and learn more about Empower BP, a global pivotal study to evaluate the ARC-IM System, an implantable neurostimulation therapy for blood pressure instability after spinal cord injury ( ). Hear directly from ONWARD, study investigators, and SCI community members who have participated in prior ARC-IM studies.

👉 Register now: https://bit.ly/4mkietd

More info: https://www.clinicaltrials.gov/study/NCT07147296

We look forward to seeing you there!

19/09/2025

We recently announced that the US FDA has approved an investigational device exemption (IDE) for the ONWARD ARC-IM System. This approval allows the initiation of Empower BP, a global pivotal study to assess the safety and efficacy of the implantable neurostimulation technology in addressing blood pressure instability following spinal cord injury.

Many people living with experience symptomatic blood pressure instability, where disruptions in the autonomic nervous system cause blood pressure to fluctuate between abnormally low and high levels. This under-appreciated and unmet need has a significant impact on both cardiovascular health and quality of life.

Join our webinar in collaboration with the Christopher & Dana Reeve Foundation to learn more about the global Empower BP pivotal study. It will feature speakers from ONWARD, study principal investigators, and SCI community members who participated in past studies investigating ARC-IM Therapy to treat symptomatic blood pressure instability.

When: September 25 at 12:00 PM ET
Register here: https://us02web.zoom.us/webinar/register/8317580514853/WN_bUdVrPSvQgmXjUwYDJf7sw #/registration

We look forward to engaging with you during this session!

For more details about the study, please visit: https://www.clinicaltrials.gov/study/NCT07147296

ARC-IM® is investigational and not available for commercial use. The safety and effectiveness of this therapy are currently being evaluated in clinical studies and are under review by the US Food and Drug Administration (FDA). Limited by United States law to investigational use.

18/09/2025

We are proud to announce the simultaneous publications of two articles in the highly respected academic journals Nature and Nature Medicine. They highlight advances in blood pressure regulation after spinal cord injury (SCI) and add to the compelling body of scientific and clinical evidence supporting the investigational ARC-IM® System, our implanted neuromodulation platform designed to deliver targeted and personalized spinal cord stimulation.

Both publications support our commitment to introducing therapies that address critical autonomic functions impacted by . These results demonstrate the potential of ARC-IM Therapy for managing blood pressure instability in advance of the planned initiation of the Empower BP global pivotal study later this year.

Read the full press release: https://lnkd.in/eahW9SSt
Nature article: https://lnkd.in/gvvJ2Mvi
Nature Medicine article: https://lnkd.in/gMf8YAyj

ARC-IM® is investigational and not available for commercial use. To stay informed about ONWARD’s technologies, research studies, and future availability in your area, please complete the webform linked in the comments below.

08/09/2025

We are pleased to announce that we have received CE Mark certification for the ARC-EX® System, enabling commercialization of our breakthrough spinal cord stimulation system in the European Union and certain other countries. This certification enables us to promote its use to improve hand strength and sensation after spinal cord injury, both in the clinic and at home.

The ARC-EX Therapy opens new doors for the European community, offering opportunities for recovery and care that were previously unavailable. It gives us great satisfaction to bring this important new therapeutic option to people living with paralysis in Europe.

Read the full press release: https://ir.onwd.com/static-files/a535cfdb-3cdf-4e12-b0fb-a22805640da0

To stay informed about ONWARD’s research studies, technologies, and the availability of therapies in your area, please complete the webform linked in the comments below.

ARC-EX Indication for Use (EU): The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic and with take-home exercises in the home to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic (>1 year post-injury), non-progressive neurological deficit resulting from an incomplete spinal cord injury (C2-C8 inclusive).

ONWARD

08/01/2026

05/01/2026

19/12/2025

11/12/2025

17/11/2025

11/11/2025

28/10/2025

17/10/2025

24/09/2025

19/09/2025

18/09/2025

08/09/2025

Adres

Website

Meldingen

Contact De Praktijk

Snelkoppelingen

Delen

Type